Liver Injury Associated with the Selective Progesterone Modulator Ulipristal.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Björnsson, Einar SIssue Date
2020-10-09
Metadata
Show full item recordCitation
Björnsson ES. Liver Injury Associated with the Selective Progesterone Modulator Ulipristal. Drug Saf. 2020 Dec;43(12):1201-1204. doi: 10.1007/s40264-020-01004-4.Additional Links
https://link.springer.com/article/10.1007%2Fs40264-020-01004-4ae974a485f413a2113503eed53cd6c53
10.1007/s40264-020-01004-4
Scopus Count
Collections
Related articles
- An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
- Authors: Kang S, Brinker A, Jones SC, Dimick-Santos L, Avigan MI
- Issue date: 2020 Dec
- Ulipristal acetate (Esmya): restrictions on use.
- Issue date: 2018 Nov
- Liver injury and ulipristal acetate: an overstated tragedy?
- Authors: Donnez J
- Issue date: 2018 Sep
- Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis.
- Authors: Gatti M, Poluzzi E, De Ponti F, Raschi E
- Issue date: 2020 Dec
- Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program.
- Authors: Donnez J, Arriagada P, Marciniak M, Larrey D
- Issue date: 2018 Dec